Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes.
Casasnovas RO, Follows G, Zijlstra JM, Vermaat JSP, Kalakonda N, Choquet S, Neste EVD, Hill B, Thieblemont C, Cavallo F, la Cruz F, Kuruvilla J, Hamad N, Jaeger U, Caimi PF, Gurion R, Warzocha K, Bakhshi S, Sancho JM, Schuster M, Egyed M, Offner F, Vassilakopoulos TP, Samal P, Ku M, Ma X, Chamoun K, Shah J, Canales M, Maerevoet M, Shacham S, Kauffman MG, Goy A.
Casasnovas RO, et al. Among authors: offner f.
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):24-33. doi: 10.1016/j.clml.2021.07.017. Epub 2021 Jul 22.
Clin Lymphoma Myeloma Leuk. 2022.
PMID: 34493477
Free article.